|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4 Pt 2
|
|
pubmed:dateCreated |
1996-11-8
|
|
pubmed:abstractText |
Symptomatic vulvovaginal candidiasis is rare in postmenopausal subjects because of the estrogen-dependence of this infection. Tamoxifen, a breast-cancer cell estrogen-antagonist, has not previously been reported to predispose to vulvovaginal candidiasis.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0029-7844
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
88
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
704-6
|
|
pubmed:dateRevised |
2009-10-26
|
|
pubmed:meshHeading |
pubmed-meshheading:8841260-Aged,
pubmed-meshheading:8841260-Aged, 80 and over,
pubmed-meshheading:8841260-Antineoplastic Agents, Hormonal,
pubmed-meshheading:8841260-Breast Neoplasms,
pubmed-meshheading:8841260-Candidiasis, Vulvovaginal,
pubmed-meshheading:8841260-Female,
pubmed-meshheading:8841260-Humans,
pubmed-meshheading:8841260-Middle Aged,
pubmed-meshheading:8841260-Postmenopause,
pubmed-meshheading:8841260-Recurrence,
pubmed-meshheading:8841260-Risk Factors,
pubmed-meshheading:8841260-Tamoxifen
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Recurrent vulvovaginal candidiasis associated with long-term tamoxifen treatment in postmenopausal women.
|
|
pubmed:affiliation |
Department of Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan, USA.
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
